A tale of two beaten biotech stocks: GNCA, AXON.
Pivotal phase 3 MINDSET trial fails, AD program discontinued, Oppenheimer moves to sidelines.
Axovant Sciences Ltd (NASDAQ:AXON) investors hit the panic button after the dementia drug maker announced that the Phase 3 MINDSET clinical trial of its investigational …
Synaptics Incorporated Top Oppenheimer analyst Andrew Uerkwitz has downgraded his rating on shares of Syros Pharmaceuticals Inc (NASDAQ:SYNA) to Sell – his first …
Axovant Sciences Ltd (NYSE:AXON) shares are falling nearly 12% following the news that Lundbeck’s experimental Alzheimer’s drug Idalopirdine failed in a late-stage study. …
Analysts are weighing in on semiconductor firm Integrated Device Technology Inc (NASDAQ:IDTI) and biopharmaceutical company Axovant Sciences Ltd (NYSE:AXON), as shares of both companies fell sharply …
In a research report issued today, Chardan analyst Gbola Amusa reiterated a Sell rating on Axovant Sciences Ltd. (NYSE:AXON) with a $9.
